ReviewFrontiers in pharmacology2023
Progression of the PI3K/Akt signaling pathway in chronic obstructive pulmonary disease.
Review in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 46 citations in OpenAlex.
- CHF6523 data suggest that the phosphoinositide 3-kinase delta isoform is not a suitable target for the management of COPD.Respiratory research · 2024Trial
- The Role of MicroRNAs Implicated in the Regulation of PI3K/AKT and Focal Adhesion Signaling Pathways in Chronic Obstructive Pulmonary Disease.Biochemical genetics · 2026Article
- Fucosyltransferases in asthma: regulators of epithelial dysfunction, senescence, and airway inflammation.Clinical reviews in allergy & immunology · 2026Review
- Multi-Omics Analysis and In Vitro Experimental Validation Identify Candidate Mechanisms of Baicalein Against Chronic Obstructive Pulmonary Disease.Molecules (Basel, Switzerland) · 2026Article
- Blood cell ratio biomarkers of systemic inflammation in chronic obstructive pulmonary disease.Respiratory research · 2026Article
- Oxidative stress-associated genes TPPP3 and VEGFA in COPD revealed by bulk and single-cell sequencing analysis.Scientific reports · 2026Article
- SULT1E1 exerts a protective role in COPD by inhibiting the AKT pathway: an in vivo and in vitro study.Scientific reports · 2026Article
- Blood Cell Ratio Biomarkers of Non-type 2 Inflammation in Chronic Obstructive Pulmonary.Research square · 2026Article
- Acute Lung Injury Induced by Hyperbaric Oxygen or Other External Factors, with a Focus on Exosomes.International journal of molecular sciences · 2026Review
- Emerging Mechanistic Links Between Fucosylation and Senescence in Lung Diseases.Journal of respiratory biology and translational medicine · 2026Article
- Identification of candidate selenium-associated transcriptomic biomarkers in chronic obstructive pulmonary disease: an integrated bioinformatics and expression validation study.Frontiers in medicine · 2026Article
- NOD1 modulates chronic obstructive pulmonary disease progression via FOXA1/NLRP3-mediated regulation of pyroptosis.Frontiers in immunology · 2026Article
- PI3K/AKT signaling pathway: new strategies for treating atherosclerosis with plant-derived compounds.Frontiers in pharmacology · 2026Review
- Crocin protects against smoke-induced chronic obstructive pulmonary disease by regulating AKT1.Frontiers in pharmacology · 2026Article
- Exploring the mechanism of guben kechuan granules in the treatment of COPD via network pharmacology, molecular docking and molecular dynamics simulations.Scientific reports · 2025Article
- Cytokine-Cytokine Receptor Interaction and Endocytosis are Common Pathways for Symptom Burden and Sickness Behavior Symptoms in Oncology Patients Undergoing Chemotherapy.Cancer medicine · 2025Article
- The Associations of Air Pollution Mixture Exposure with Plasma Proteins in an Elderly U.S. Panel.Environmental science & technology · 2025Article
- Research advances in polyphenols from Chinese herbal medicine for the prevention and treatment of chronic obstructive pulmonary disease: a review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- Impairing Ferroptosis Through the PI3K/Akt/Nrf2 Pathway: The Way for Nerve Growth Factor to Mitigate Hypoxia-induced Cardiomyocyte Damage.Cell biochemistry and biophysics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic Obstructive Pulmonary Disease (COPD) is a chronic respiratory disease characterized by a slow progression and caused by the inhalation of harmful particulate matter. Cigarette smoke and air pollutants are the primary contributing factors. Currently, the pathogenesis of COPD remains incompletely understood. The PI3K/Akt signaling pathway has recently emerged as a critical regulator of inflammation and oxidative stress response in COPD, playing a pivotal role in the disease's progression and treatment. This paper reviews the association between the PI3K/Akt pathway and COPD, examines effective PI3K/Akt inhibitors and novel anti-COPD agents, aiming to identify new therapeutic targets for clinical intervention in this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.